Dopamine Dysregulation a Causative Culprit in Schizophrenia?

A genetic postmortem analysis of the brains of patients with schizophrenia suggests a dysfunction of dopamine receptors in the caudate nucleus may cause the disorder. Investigators have identified a mechanism on the dopamine receptor, known as the autoreceptor, which regulates how much dopamine is released from the presynaptic neuron. Impairment of this autoreceptor leads to … Read more

Menopause an Independent Risk Factor for Schizophrenia Relapse?

Menopause appears to be an independent risk factor for relapse in women with schizophrenia spectrum disorders (SSDs), new research suggests. Investigators studied a cohort of close to 62,000 people with SSDs, stratifying individuals by sex and age, and found that starting between the ages of 45 and 50 years — when the menopausal transition is … Read more

‘Amazing’ Phase 3 Results for Novel Schizophrenia Combo Drug

VIENNA — The investigational agent xanomeline-trospium (KarXT, Karuna Therapeutics) achieves significant and clinically meaningful improvements in schizophrenia symptom scores without causing problematic adverse effects, new research suggests. Results from the phase 3 EMERGENT-2 trial, which included more than 250 patients with schizophrenia, showed that those who received xanomeline-trospium for 5 weeks achieved a significant reduction … Read more

Schizophrenia, Postmodernism: A Philosophical Treatment Exercise

Schizophrenia is defined as having episodes of psychosis: periods of time when one suffers from delusions, hallucinations, disorganized behaviors, disorganized speech, and negative symptoms. The concept of schizophrenia can be simplified as a detachment from reality. Patients who struggle with this illness frame their perceptions with a different set of rules and beliefs than the … Read more

Baseline Neuromotor Abnormalities Persist in Schizophrenia

Baseline dyskinesia and neurological soft signs (NSS) predicted the disease process of schizophrenia over a 21-year follow-up period, based on data from 243 adult patients. Neuromotor abnormalities in psychotic disorders have long been ignored as side effects of antipsychotic drugs, but they are gaining new attention as a component of the disease process, with implications … Read more

Clozapine Best Choice for Reducing SUD Risk in Schizophrenia?

Clozapine or antipsychotic polytherapy appear to be the best approach in reducing the risk for a substance use disorder (SUD) in adults with schizophrenia and for preventing relapse in patients with both diagnoses, results of a real-world study show. “Our findings are in line with a recent meta-analysis showing superior efficacy of clozapine in schizophrenia … Read more

LAIAs More Effective Than Oral Antipsychotics for Schizophrenia

For patients with schizophrenia, long-acting injectable antipsychotics (LAIAs) are associated with a lower risk than oral antipsychotics (OAs) for disease relapse and hospitalization ― and they carry no increased risk for adverse events, new research shows. Investigators analyzed data for more than 70,000 patients with schizophrenia and found that, compared with OAs, LAIAs were associated … Read more

Dermatologists Want Training in Antipsychotic Prescribing for DI

GLASGOW — Dermatologists do not feel confident in independently prescribing antipsychotic medications for patients with delusional infestation, shows a UK survey that also indicated there is a clear demand for training in prescribing these drugs. Delusional infestation is a rare disorder characterized by an individual’s belief that his or her skin, body, or immediate environment … Read more

Best Strategy to Prevent Schizophrenia Relapse Identified?

A large meta-analysis sheds light on the best antipsychotic maintenance strategy to prevent relapse in clinically-stable schizophrenia — with some unexpected results that have potential implications for changes to current guidelines. Consistent with the researchers’ hypothesis, continuing antipsychotic treatment at the standard dose, switching to another antipsychotic, and reducing the dose were all significantly more … Read more

Lower-Dose Antipsychotics Benefit Patients with Schizophrenia

NEW ORLEANS — Patients with treatment-refractory schizophrenia in a long-term forensic facility showed significant stability following reduced doses of long-acting injectable antipsychotics, a study revealed. Dr Mujeeb Shad “There is an argument by some experts in the field that state hospital populations represent a different set of patients who require higher antipsychotic dosages, with no … Read more